Pre-Open Stock Movers 08/10: (CLNE) (OCN) (HRTX) (YELP) Higher; (GEVO) (SPWR) (MYGN) (PRGO) Lower (more...)

UBS Raises Price Target on Ralph Lauren (RL) to $117; Reiterates Buy

UBS reiterated a Buy rating on Ralph Lauren (NYSE: RL), and raised the price target to $117.00 (from $115.00), following the company's 1Q earnings report. RL delivered revenues in line with its MSD% guidance, and guided 2Q revenues to M/HSD% above consensus at -10%.

Analyst Michael Binetti commented,... More

Leerink Partners Remains Sidelined on Perrigo (PRGO) Following Mixed 2Q

Leerink Partners maintained a Market Perform rating on Perrigo Co. (NYSE: PRGO), and cut the price target to $81.00 (from $96.00), following the company's 2Q earnings report. PRGO reported a modest beat on top line, but missed EPS by 3%.

Analyst Jason Gerberry commented,... More

Jefferies Raises Price Target on JD.com (JD) to $32 Following 2Q

Jefferies reiterated a Buy rating on JD.com, Inc (NASDAQ: JD), and raised the price target to $32.00 (from $31.60), following the company's 2Q earnings report. Revenue grew 42% yoy to RMB65.2bn, in line with management guidance and consensus. Management guided 3Q16 revenue at... More

Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q

Jefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More

Imperial Capital Raises Price Target on CyberArk Software (CYBR) to $55 Following 2Q

Imperial Capital reiterated an In-Line rating on CyberArk Software (NASDAQ: CYBR), and raised the price target to $55.00 (from $45.00), following the company's 2Q earnings report. CYBR reported revenue of $50.4mn and adjusted EPS of $0.29, compared with the Street revenue estimates of 48.3mn and adjusted EPS estimates... More

RBC Capital Remains Sidelined on Wendy's (WEN) Following 2Q

RBC Capital reiterated a Sector Perform rating and $11.00 price target on Wendy's (NASDAQ: WEN) following the company's 2Q earnings report. While the company expressed confidence that it could deliver positive SSS in 2H, RBC continues to worry about Wendys ability to lap its difficult... More

FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval

Below is the FDA's approval letter Heron Therapeutics' (Nasdaq: HRTX) SUSTOL: